Get the Stockscreener App
55.05
1.42%
0.77
After Hours:
54.99
-0.06
-0.11%
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $55.05, with a volume of 16.13M.
It is up +1.42% in the last 24 hours and up +1.55% over the past month.
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$54.28
Open:
$54.53
24h Volume:
16.13M
Relative Volume:
1.08
Market Cap:
$112.07B
Revenue:
$48.03B
Net Income/Loss:
$6.05B
P/E Ratio:
18.59
EPS:
2.9615
Net Cash Flow:
$15.30B
1W Performance:
+0.73%
1M Performance:
+1.55%
6M Performance:
+19.73%
1Y Performance:
-6.92%
1-Day Range:
$54.33
$55.07
1-Week Range:
$54.21
$56.12
52-Week Range:
$42.52
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
55.05 | 110.50B | 48.03B | 6.05B | 15.30B | 2.9615 |
|
LLY
Lilly Eli Co
|
1,037.15 | 916.62B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
227.25 | 547.61B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
223.01 | 389.58B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
148.68 | 285.73B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
110.27 | 268.90B | 63.90B | 19.05B | 13.05B | 7.5596 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Upgrade | UBS | Neutral → Buy |
| Dec-15-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-12-25 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-05-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Apr-22-25 | Initiated | Piper Sandler | Overweight |
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
How Investors May Respond To Bristol Myers Squibb (BMY) Expanding AI-Enabled Oncology Partnerships - simplywall.st
Piper Sandler Raises Bristol Myers (BMY) PT to $66 Citing Pipeline Visibility - Insider Monkey
Bristol-Myers Squibb Expands Cancer Efforts With New AI And Drug Deals - Yahoo Finance Singapore
Bristol-Myers Squibb Cancer And AI Deals Put Valuation In Focus - simplywall.st
Citi Raises Bristol-Myers (BMY) Target as Sector Outlook Improves into 2026 - Finviz
Will BMY's Oncology Collaborations Drive Its Next Growth Phase? - TradingView
Janux hires CMO after T cell engager deal with Bristol Myers; A batch of appointments at Lexeo - Endpoints News
How Covington’s Dargan Led $18 Billion in Bristol Myers Deals - Bloomberg Law News
A Look At Bristol Myers Squibb (BMY) Valuation After Recent Share Price Momentum - simplywall.st
Bristol Myers moves SC to stop Zydus from selling biosimilar cancer drug - The Economic Times
Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for - Finviz
Ruffer LLP Invests $6.84 Million in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Stock Position Increased by Mirae Asset Global Investments Co. Ltd. - MarketBeat
AustralianSuper Pty Ltd Lowers Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Is Bristol Myers Squibb (BMY) Pricing Reflect Its Fundamentals After A Steady Share Performance - simplywall.st
Bristol Myers Squibb (BMY), Microsoft (MSFT) Partner to Enhance Early Lung Cancer Detection Through AI - Finviz
Bristol Myers Squibb (BMY) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
P/E Ratio Insights for Bristol-Myers SquibbBristol-Myers Squibb (NYSE:BMY) - Benzinga
Bristol-Myers Squibb (BMY) Sees Price Target Raised by Piper San - GuruFocus
Morgan Stanley Maintains Bristol-Myers Squibb(BMY.US) With Sell Rating, Maintains Target Price $37 - 富途牛牛
BMS-Partnered Cellares Raises $257M for Cell Therapy Manufacturing Expansion - BioSpace
General Motors To Rally More Than 27%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
Bristol Myers Squibb (BMY) Exec Joins Pacira BioSciences Board - GuruFocus
Citi Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Maintains Target Price $60 - 富途牛牛
Shareholders in Bristol-Myers Squibb (NYSE:BMY) are in the red if they invested three years ago - Yahoo Finance
Bristol-Myers Squibb Co (NYSE:BMY) Shows Strong Technical Setup for Potential Breakout - Chartmill
Medicare Targets 15 High-Profile Drugs In Third Price Negotiation Cycle - Benzinga
Bristol-Myers Squibb Stock Outlook: Is Wall Street Bullish or Bearish? - Yahoo Finance
Janux Therapeutics Partners With Bristol-Myers (BMY) on Solid Tumor Therapy - Finviz
Bristol-Myers Squibb (BMY) Leads Record Lobbying Surge in Health - GuruFocus
Bristol-Myers Squibb Stock: A Deep Dive Into Analyst Perspectives (12 Ratings) - Benzinga
Autologous Cell Therapy Market Size to Reach US$ 44.55 Billion by 2033 | Astute Analytica - GlobeNewswire Inc.
Citi Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Announces Target Price $60 - 富途牛牛
Bristol-Myers Squibb (BMY) Stock Analysis: Evaluating the 4.61% Dividend Yield and Growth Outlook - DirectorsTalk Interviews
What the Options Market Tells Us About Bristol-Myers Squibb - Benzinga
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know - Yahoo Finance
Bristol Myers Squibb Company $BMY Shares Sold by Quilter Plc - MarketBeat
Resona Asset Management Co. Ltd. Lowers Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb: The Rerating Was FastThe Proof Will Be Slow (Rating Downgrade) - Seeking Alpha
AI Bubble or Sustainable Growth? Here Are 2 Healthcare Companies Harnessing AI for the Long Term. - Finviz
Reassessing Bristol Myers Squibb (BMY) After Mixed Returns And Product Pipeline Developments - Yahoo Finance
Bristol Myers Squibb and Janux Launch Partnership on Tumor-Activated T Cell Engagers - Oncodaily
Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead? - Finviz
Bristol-Myers Squibb and BioNTech Advance New Phase 3 Lung Cancer Trial With Pumitamig - TipRanks
A Look At Bristol Myers Squibb (BMY) Valuation After New Microsoft AI Pact And Camzyos Trial Results - Yahoo Finance
JANX Enters Global Oncology Collaboration With BMY, Stock Rises - Finviz
BMS snags top neuro researcher from Eisai—Chutes & Ladders - Fierce Biotech
Oncolytic Virotherapy Market - GlobeNewswire Inc.
Did AI Lung Imaging And New HCM Data Just Shift Bristol Myers Squibb’s (BMY) Investment Narrative? - simplywall.st
Janux, Bristol Myers Squibb partner on tumor-activated therapy By Investing.com - Investing.com Nigeria
Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million - Benzinga
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):